Newly found workings of Pseudomonas aeruginosa may explain why certain medications are only modestly effective in patients with cystic fibrosis. A group of researchers led by Dr. Pradeep Singh and Dr. Peter Jorth at the University of Washington School of Medicine discovered that when P. aeruginosa infects cystic fibrosis patients’…
News
Global biotechnology company and Cystic Fibrosis therapeutic leader Vertex, together with the University of Massachusetts (UMass), recently revealed the awardees of the yearly Vertex Science Leaders Scholarship, which will fund 4 years of their education in any Science, Technology, Engineering and Math (STEM) course at any UMass campus. This scholarship is part…
The CF Foundation’s Cystic Fibrosis Research Development Program (RDP) recently expanded its network to include new CF centers in Denver and Atlanta, two cities that house the two largest CF treatment centers in the country. The new RDP in Denver, Colorado will be awarded to $2.1 million in funding, to be…
A study recently published in the journal PLoS One reported on the effectiveness of a new diagnostic tool for detecting pulmonary diseases in children, including cystic fibrosis (CF). The study was led by researchers at the Hanover Medical School in Germany and is entitled “…
In a new study entitled “Cysteamine as a future intervention in cystic fibrosis against current and emerging pathogens: a patient-based ex vivo study confirming its antimicrobial and mucoactive potential in sputum,” a team of scientists show for the first time that NovaBiotics’ therapy for Cystic Fibrosis, Cysteamine…
The Mauli Ola Foundation is crossing the country once again to support patients who suffer from cystic fibrosis (CF). The organization is hosting the East Coast Tour from Texas to New York until August 28, and this year the event is being held under the name “The Humuhumunukunukuapua’a…
Dr. Basil Hubbard, an assistant professor of pharmacology in the University of Alberta’s Faculty of Medicine & Dentistry envisions a new world of therapeutic treatments for millions of patients that could be just over the horizon — a future in which genetic diseases like muscular dystrophy, cystic fibrosis, and…
A study recently published in the journal SpringerPlus revealed new insights into the pulmonary microbiota in patients with cystic fibrosis and the impact of Pseudomonas aeruginosa infection. The study is entitled “Insights into the respiratory tract microbiota of patients with cystic fibrosis during early…
Patients living with cystic fibrosis (CF) are at increased risk for acquiring and developing severe respiratory infections. The most worrisome pathogen is Pseudomonas aeruginosa (PsA), which is treated with powerful antibiotics either via oral, intravenous, or inhaled antibiotics. While these treatments are known to work, there has yet to be a conclusive…
La Jolla Pharmaceutical Company has just announced it has entered two exclusive licensing agreements with the Indiana University Research and Technology Corporation (IURTC), and the IURTC and the University of Alabama at Birmingham (UAB). The agreements cover intellectual property rights for the company’s next-gen gentamicin derivatives, LJPC-30Sa and LJPC-30Sb, as antimicrobial agents…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.